Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: Thiazolidine Linkers ...
Routine Notice Added Draft

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a United States patent application, specifically US20260083856A1, filed on September 11, 2025. The application describes novel thiazolidine (Tz) linkers designed for creating protein-drug conjugates, along with methods for their production and their application in treating diseases or disorders.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future intellectual property developments in the field of protein-drug conjugates. Companies involved in drug development, particularly those working with antibody-drug conjugates or similar targeted therapies, should monitor this application and related patents for potential licensing opportunities or competitive landscape shifts.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

THIAZOLIDINE LINKERS FOR PROTEIN-DRUG CONJUGATES AND USES THEREOF

Application US20260083856A1 Kind: A1 Mar 26, 2026

Inventors

Xiao Cai, Stepan Chuprakov, Reji Nair, Ayodele Ogunkoya, Matthew Smith

Abstract

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.

CPC Classifications

A61K 47/6851 A61K 47/6803 A61K 47/6889 C07K 16/32 C07K 2317/40 C07K 2317/94

Filing Date

2025-09-11

Application No.

19325974

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 11th, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260083856A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Conjugate Chemistry
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Drug Development Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!